UNITED STATES DISTRICT COURT DISTRICT OF MASSACHUSETTS

IN RE PHARMACEUTICAL INDUSTRY AVERAGE WHOLESALE PRICE LITIGATION) MDL NO. 1456) Civil Action No. 01-12257-PBS) Subcategory No. 03-10643
THIS DOCUMENT RELATES TO:)) Judge Patti B. Saris
The City of New York, et al.	
v.)
Abbott Laboratories, Inc., et al.)

DECEMBER 2011 STATUS REPORT ON BEHALF OF THE CITY OF NEW YORK AND NEW YORK COUNTIES

The undersigned counsel for the City of New York and New York Counties in the above-captioned action (hereinafter referred to as "plaintiffs") hereby submit the attached Status Report for December 2011, in accordance with the Court's June 17, 2004 Procedural Order.

Dated: December 1, 2011

Respectfully submitted,

City of New York and New York Counties in MDL 1456 except Nassau and Orange, by

KIRBY McINERNEY, LLP

825 Third Avenue New York, New York 10022 (212) 371-6600

By: /s/ Joanne M. Cicala Joanne M. Cicala Ross B. Brooks, Esq.
MILBERG LLP
One Pennsylvania Plaza
New York, NY 10119
(212) 594-5300
Special Counsel for the County of Nassau

Theresa A. Vitello, Esq. LEVY PHILLIPS & KONIGSBERG, LLP 800 Third Avenue New York, NY 10022 (212) 605-6205 Counsel for the County of Orange

December 2011 Status Report on Behalf of the City of New York and New York Counties

Voluntary Dismissal of Claims

On June 2, 2011, plaintiffs filed a notice of voluntary dismissal of claims against defendant Endo Pharmaceuticals, Inc. *See* Docket No. 7576, Sub-docket No. 290. This notice remains *sub judice*.

On November 18, 2011, plaintiffs filed a notice of voluntary dismissal with prejudice of claims against defendants Merck & Co., Inc. (f/k/a Schering-Plough Corporation), Schering Corporation, and Warrick Pharmaceuticals Corporation. *See* Docket No. 7921, Sub-docket 310. This notice remains *sub judice*.

On November 22, 2011, plaintiffs filed a notice of voluntary dismissal of claims with prejudice against defendant Merck, Sharp & Dohme Corp. (f/k/a Merck & Co., Inc.). *See* Docket No. 7930, Sub-docket 311. This notice remains *sub judice*.

Settlement Order of Dismissal

On October 6, 2011, the court entered plaintiffs and defendants' joint motion to extend the settlement order of dismissal as to Alpharma Inc., Purepac Pharmaceutical Co., King Pharmaceuticals Inc., King Research and Development, Monarch Pharmaceuticals Inc., Merck & Co. Inc., Mylan Laboratories Inc., Mylan Pharmaceuticals Inc., UDL Laboratories Inc., Par Pharmaceutical Companies, Inc., Par Pharmaceutical Inc., Roche Laboratories Inc., Hoffman-La Roche Inc., Schering-Plough Corp., Schering Corporation, Warrick Pharmaceuticals Corporation and TAP Pharmaceutical Products Inc. The order provides that claims against these defendants shall be dismissed without costs and without prejudice to the right of any party, upon good cause shown, to reopen the action by December 5, 2011 if settlement is not consummated. *See* the

Court's October 6, 2011 Electronic Order granting Docket No. 7827, Sub-docket No. 304.

On November 1, 2011, the Court entered plaintiffs' and defendant Sandoz, Inc.'s joint proposed settlement order of dismissal of claims against defendant Sandoz, Inc. The order provides that claims against this defendant shall be dismissed without cost and without prejudice of any party, upon good cause shown, to reopen the action within one hundred and twenty (120) days if settlement is not consummated. *See* Docket No. 7871, Sub-docket No. 307.

CERTIFICATE OF SERVICE

I, Kathryn Allen, hereby certify that on the 1st day of December, 2011, I caused a true and correct copy of the above December 2011 Status Report for the City of New York and New York Counties to be delivered to counsel of record for defendants by electronic service pursuant to Case Management Order No. 2 entered by the Honorable Patti B. Saris in MDL No. 1456.

Dated: December 1, 2011

/s/ Kathryn B. Allen Kathryn B. Allen Kirby McInerney LLP 825 Third Avenue New York, NY 10022 (212) 371-6600